PLAU

Item Information
Catalog #
Size
Price
Description

This gene encodes a secreted serine protease that converts plasminogen to plasmin. The encoded preproprotein is proteolytically processed to generate A and B polypeptide chains. These chains associate via a single disulfide bond to form the catalytically inactive high molecular weight urokinase-type plasminogen activator (HMW-uPA). HMW-uPA can be further processed into the catalytically active low molecular weight urokinase-type plasminogen activator (LMW-uPA). This low molecular weight form does not bind to the urokinase-type plasminogen activator receptor. Mutations in this gene may be associated with Quebec platelet disorder and late-onset Alzheimer's disease. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed.

Product Overview
Entrez GenelD
5328
Aliases
ATF; QPD; UPA; URK; u-PA; BDPLT5
Clone#
6B6A3
Host / Isotype
Mouse / Mouse IgG1
Species Reactivity
Human
Immunogen
Purified recombinant fragment of human PLAU (AA: 107-379) expressed in E. Coli.
Formulation
Purified antibody in PBS with 0.05% sodium azide
Storage
4℃; -20℃ for long term storage
Product Applications
WB (Western Blot)
1/500 - 1/2000
ICC (Immunocytochemistry)
1/200 - 1/1000
FCM (Flow Cytometry)
1/200 - 1/400
ELISA
1/10000
References
1.Biochim Biophys Acta Proteins Proteom.2021 Feb;1869(2):140562.
2.Molecules.2021 Mar 24;26(7):1816.
Product Image
Elisa
Figure 1:Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)
Figure 1:Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)
Western Blot
Figure 2:Western blot analysis using PLAU mAb against human PLAU (AA: 107-379) recombinant protein. (Expected MW is 34 kDa)
Figure 2:Western blot analysis using PLAU mAb against human PLAU (AA: 107-379) recombinant protein. (Expected MW is 34 kDa)
Western Blot
Figure 4:Western blot analysis using PLAU mouse mAb against PC-3 (1),MCF-7 (2), LNCap (3),DU145 (4),HCT116 (5),A549 (6),SK-OV-3 (7) and HEK293 (8) cell lysate.
Figure 4:Western blot analysis using PLAU mouse mAb against PC-3 (1),MCF-7 (2), LNCap (3),DU145 (4),HCT116 (5),A549 (6),SK-OV-3 (7) and HEK293 (8) cell lysate.
Immunohistochemical analysis
Figure 5:Immunofluorescence analysis of Hela cells using PLAU mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)
Figure 5:Immunofluorescence analysis of Hela cells using PLAU mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)
Immunofluorescence analysis
Figure 6:Flow cytometric analysis of Hela cells using PLAU mouse mAb (green) and negative control (red).
Figure 6:Flow cytometric analysis of Hela cells using PLAU mouse mAb (green) and negative control (red).
Immunofluorescence analysis
Figure 7:Flow cytometric analysis of HepG2 cells using PLAU mouse mAb (green) and negative control (red).
Figure 7:Flow cytometric analysis of HepG2 cells using PLAU mouse mAb (green) and negative control (red).
For Research Use Only. Not for use in diagnostic procedures.